Literature DB >> 20472288

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.

Sundar Jagannath1, Meletios A Dimopoulos, Sagar Lonial.   

Abstract

Multiple myeloma (MM) is an incurable disease characterized by the accumulation of malignant plasma cells in the bone marrow. Recently, an improved understanding of the biology of the disease has led to the development of targeted agents such as the proteasome inhibitor bortezomib and the immunomodulatory agents thalidomide and lenalidomide; however, MM remains incurable. The combination of bortezomib and an HDAC inhibitor synergistically induces MM cell apoptosis and may be of value in the treatment of patients with relapsed/refractory MM. This review examines the potential of combined proteasome and HDAC inhibition in the treatment of relapsed/refractory MM. Copyright 2010. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20472288     DOI： 10.1016/j.leukres.2010.04.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  20 in total

1.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authors:  Loredana Santo; Teru Hideshima; Andrew L Kung; Jen-Chieh Tseng; David Tamang; Min Yang; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Walter C Ogier; Diana Cirstea; Scott Rodig; Homare Eda; Tyler Scullen; Miriam Canavese; James Bradner; Kenneth C Anderson; Simon S Jones; Noopur Raje
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

2.  Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid.

Authors:  Kanagaraj Subramanian; Darren M Hutt; Samantha M Scott; Vijay Gupta; Shu Mao; William E Balch
Journal:  J Biol Chem       Date:  2020-04-30       Impact factor: 5.157

Review 3.  Bortezomib for the treatment of non-Hodgkin's lymphoma.

Authors:  Prithviraj Bose; Michael S Batalo; Beata Holkova; Steven Grant
Journal:  Expert Opin Pharmacother       Date:  2014-09-29       Impact factor: 3.889

4.  In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.

Authors:  Girija Dasmahapatra; Hiral Patel; Johnathan Friedberg; Steven N Quayle; Simon S Jones; Steven Grant
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

5.  Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.

Authors:  Grant L Lin; Kelli M Wilson; Michele Ceribelli; Benjamin Z Stanton; Pamelyn J Woo; Sara Kreimer; Elizabeth Y Qin; Xiaohu Zhang; James Lennon; Surya Nagaraja; Patrick J Morris; Michael Quezada; Shawn M Gillespie; Damien Y Duveau; Aleksandra M Michalowski; Paul Shinn; Rajarshi Guha; Marc Ferrer; Carleen Klumpp-Thomas; Sam Michael; Crystal McKnight; Paras Minhas; Zina Itkin; Eric H Raabe; Lu Chen; Reem Ghanem; Anna C Geraghty; Lijun Ni; Katrin I Andreasson; Nicholas A Vitanza; Katherine E Warren; Craig J Thomas; Michelle Monje
Journal:  Sci Transl Med       Date:  2019-11-20       Impact factor: 17.956

6.  Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency.

Authors:  Marion Bouchecareilh; Darren M Hutt; Patricia Szajner; Terence R Flotte; William E Balch
Journal:  J Biol Chem       Date:  2012-09-20       Impact factor: 5.157

7.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Authors:  John D Shaughnessy; Pingping Qu; Saad Usmani; Christoph J Heuck; Qing Zhang; Yiming Zhou; Erming Tian; Ichiro Hanamura; Frits van Rhee; Elias Anaissie; Joshua Epstein; Bijay Nair; Owen Stephens; Ryan Williams; Sarah Waheed; Yazan Alsayed; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

Review 8.  Multiple Myeloma: Treatment is Getting Individualized.

Authors:  M B Agarwal
Journal:  Indian J Hematol Blood Transfus       Date:  2015-07-26       Impact factor: 0.900

Review 9.  Targeting the histone orthography of cancer: drugs for writers, erasers and readers.

Authors:  Laia Simó-Riudalbas; Manel Esteller
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

10.  Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.

Authors:  Subrahmanya D Vallabhapurapu; Sunil K Noothi; Derek A Pullum; Charles H Lawrie; Rachel Pallapati; Veena Potluri; Christian Kuntzen; Sohaib Khan; David R Plas; Robert Z Orlowski; Marta Chesi; W Michael Kuehl; P Leif Bergsagel; Michael Karin; Sivakumar Vallabhapurapu
Journal:  Nat Commun       Date:  2015-10-12       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.